Vaxcyte (NASDAQ:PCVX – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Institutional and Insider Ownership
96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Vaxcyte and Brainstorm Cell Therapeutics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vaxcyte | N/A | N/A | -$402.27 million | ($4.28) | -17.68 |
| Brainstorm Cell Therapeutics | N/A | N/A | -$17.19 million | ($0.32) | -1.01 |
Analyst Ratings
This is a summary of current ratings and recommmendations for Vaxcyte and Brainstorm Cell Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vaxcyte | 0 | 0 | 4 | 0 | 3.00 |
| Brainstorm Cell Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Vaxcyte presently has a consensus price target of $78.50, suggesting a potential upside of 3.74%. Brainstorm Cell Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 520.35%. Given Brainstorm Cell Therapeutics’ higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Vaxcyte.
Profitability
This table compares Vaxcyte and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vaxcyte | N/A | -28.83% | -26.89% |
| Brainstorm Cell Therapeutics | N/A | N/A | -431.16% |
Risk & Volatility
Vaxcyte has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.
Summary
Brainstorm Cell Therapeutics beats Vaxcyte on 6 of the 10 factors compared between the two stocks.
About Vaxcyte
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
